Gynecological cancer: First-line bevacizumab for ovarian cancer—new standard of care? View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-04

AUTHORS

Susana Banerjee, Stan B. Kaye

ABSTRACT

Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease.

PAGES

194

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28

DOI

http://dx.doi.org/10.1038/nrclinonc.2012.28

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017213493

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22371131


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ovarian Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Standard of Care", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JB, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Banerjee", 
        "givenName": "Susana", 
        "id": "sg:person.01326353035.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326353035.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaye", 
        "givenName": "Stan B.", 
        "id": "sg:person.010545363662.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010545363662.22"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0959-8049(11)70155-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017540844"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2007.01.038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023390376"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2011.32", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027641359", 
          "https://doi.org/10.1038/nrclinonc.2011.32"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.42.0505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028708792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.42.0505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028708792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1104390", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035779003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1104390", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035779003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1103799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052109861"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1103799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052109861"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.18_suppl.lba5007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083951206"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-04", 
    "datePublishedReg": "2012-04-01", 
    "description": "Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease.", 
    "genre": "non_research_article", 
    "id": "sg:pub.10.1038/nrclinonc.2012.28", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1034153", 
        "issn": [
          "1759-4774", 
          "1759-4782"
        ], 
        "name": "Nature Reviews Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Gynecological cancer: First-line bevacizumab for ovarian cancer\u2014new standard of care?", 
    "pagination": "194", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "520348fc0da1faf9b5f55615c0a5dd84f6b78188e712be0d94fe7b26ccde9064"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22371131"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101500077"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/nrclinonc.2012.28"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017213493"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/nrclinonc.2012.28", 
      "https://app.dimensions.ai/details/publication/pub.1017213493"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000451.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/nrclinonc.2012.28"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.28'


 

This table displays all metadata directly associated to this object as RDF triples.

137 TRIPLES      21 PREDICATES      45 URIs      30 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/nrclinonc.2012.28 schema:about N0169d9eccd6a4a2aa3c1646897de0a8e
2 N34d5ee0ec8d847809867d99937155ce5
3 N3fbf7d0a0b604238a60c1a81fa5ec07f
4 N4734d7bed56345068e635d68bc4288c6
5 N527487eed0a243b2a1e3722a87859bd1
6 N871df70d6cba4266af77ff17e1490dc2
7 Nb0db99b89b284761a655e2a0c54a54bf
8 Ndedcd9bfbd0644839d777914534bf3cf
9 Nf344714789f64c0fad6a02f89c4c6bcf
10 anzsrc-for:11
11 anzsrc-for:1112
12 schema:author N907ef3b510dd448981f6f90831c6c2e0
13 schema:citation sg:pub.10.1038/nrclinonc.2011.32
14 https://doi.org/10.1016/j.ygyno.2007.01.038
15 https://doi.org/10.1016/s0959-8049(11)70155-1
16 https://doi.org/10.1056/nejmoa1103799
17 https://doi.org/10.1056/nejmoa1104390
18 https://doi.org/10.1200/jco.2011.29.18_suppl.lba5007
19 https://doi.org/10.1200/jco.2012.42.0505
20 schema:datePublished 2012-04
21 schema:datePublishedReg 2012-04-01
22 schema:description Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease.
23 schema:genre non_research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N900f3911f12045c7811658504a19d297
27 Ne43d5c673928401ba828509b729f6b0b
28 sg:journal.1034153
29 schema:name Gynecological cancer: First-line bevacizumab for ovarian cancer—new standard of care?
30 schema:pagination 194
31 schema:productId N14e33e668be742c884c700387c1d1732
32 N227a3a6dfe93436e83ba1e6f7498b65a
33 N282c8c3f3e7c45fea503825abea362ca
34 Ncd8c2e754bd9424eb41efcc8600ba9ed
35 Ne39987fc1ad44899979bec337b9a413a
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017213493
37 https://doi.org/10.1038/nrclinonc.2012.28
38 schema:sdDatePublished 2019-04-10T15:41
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher Ne3853274e6ad4ae6a70af4402d2f7ce7
41 schema:url https://www.nature.com/articles/nrclinonc.2012.28
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N0169d9eccd6a4a2aa3c1646897de0a8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
46 schema:name Humans
47 rdf:type schema:DefinedTerm
48 N14e33e668be742c884c700387c1d1732 schema:name readcube_id
49 schema:value 520348fc0da1faf9b5f55615c0a5dd84f6b78188e712be0d94fe7b26ccde9064
50 rdf:type schema:PropertyValue
51 N227a3a6dfe93436e83ba1e6f7498b65a schema:name doi
52 schema:value 10.1038/nrclinonc.2012.28
53 rdf:type schema:PropertyValue
54 N282c8c3f3e7c45fea503825abea362ca schema:name dimensions_id
55 schema:value pub.1017213493
56 rdf:type schema:PropertyValue
57 N34d5ee0ec8d847809867d99937155ce5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Clinical Trials as Topic
59 rdf:type schema:DefinedTerm
60 N3fbf7d0a0b604238a60c1a81fa5ec07f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Prognosis
62 rdf:type schema:DefinedTerm
63 N4734d7bed56345068e635d68bc4288c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Ovarian Neoplasms
65 rdf:type schema:DefinedTerm
66 N4a26b0437e16418999cf9c7374e6de8e rdf:first sg:person.010545363662.22
67 rdf:rest rdf:nil
68 N527487eed0a243b2a1e3722a87859bd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Antibodies, Monoclonal, Humanized
70 rdf:type schema:DefinedTerm
71 N871df70d6cba4266af77ff17e1490dc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Angiogenesis Inhibitors
73 rdf:type schema:DefinedTerm
74 N900f3911f12045c7811658504a19d297 schema:issueNumber 4
75 rdf:type schema:PublicationIssue
76 N907ef3b510dd448981f6f90831c6c2e0 rdf:first sg:person.01326353035.21
77 rdf:rest N4a26b0437e16418999cf9c7374e6de8e
78 Nb0db99b89b284761a655e2a0c54a54bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Female
80 rdf:type schema:DefinedTerm
81 Ncd8c2e754bd9424eb41efcc8600ba9ed schema:name pubmed_id
82 schema:value 22371131
83 rdf:type schema:PropertyValue
84 Ndedcd9bfbd0644839d777914534bf3cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Standard of Care
86 rdf:type schema:DefinedTerm
87 Ne3853274e6ad4ae6a70af4402d2f7ce7 schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 Ne39987fc1ad44899979bec337b9a413a schema:name nlm_unique_id
90 schema:value 101500077
91 rdf:type schema:PropertyValue
92 Ne43d5c673928401ba828509b729f6b0b schema:volumeNumber 9
93 rdf:type schema:PublicationVolume
94 Nf344714789f64c0fad6a02f89c4c6bcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Bevacizumab
96 rdf:type schema:DefinedTerm
97 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
98 schema:name Medical and Health Sciences
99 rdf:type schema:DefinedTerm
100 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
101 schema:name Oncology and Carcinogenesis
102 rdf:type schema:DefinedTerm
103 sg:journal.1034153 schema:issn 1759-4774
104 1759-4782
105 schema:name Nature Reviews Clinical Oncology
106 rdf:type schema:Periodical
107 sg:person.010545363662.22 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
108 schema:familyName Kaye
109 schema:givenName Stan B.
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010545363662.22
111 rdf:type schema:Person
112 sg:person.01326353035.21 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
113 schema:familyName Banerjee
114 schema:givenName Susana
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326353035.21
116 rdf:type schema:Person
117 sg:pub.10.1038/nrclinonc.2011.32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027641359
118 https://doi.org/10.1038/nrclinonc.2011.32
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1016/j.ygyno.2007.01.038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023390376
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1016/s0959-8049(11)70155-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017540844
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1056/nejmoa1103799 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052109861
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1056/nejmoa1104390 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035779003
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1200/jco.2011.29.18_suppl.lba5007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083951206
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1200/jco.2012.42.0505 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028708792
131 rdf:type schema:CreativeWork
132 https://www.grid.ac/institutes/grid.424926.f schema:alternateName Royal Marsden Hospital
133 schema:name The Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
134 rdf:type schema:Organization
135 https://www.grid.ac/institutes/grid.5072.0 schema:alternateName Royal Marsden NHS Foundation Trust
136 schema:name The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JB, UK
137 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...